BioCentury
ARTICLE | Clinical News

Viibryd vilazodone: Phase III data

June 30, 2014 7:00 AM UTC

Top-line data from the double-blind, U.S. Phase III MD-05 trial in 680 adults with GAD showed that a 40 mg/day fixed dose of oral Viibryd met the primary endpoint of improving HAM-A total score from b...